1. Treatment of multiple sclerosis: role of natalizumab

   • Giancarlo Comi

   MS Treatment 01 November 2009 Pages: 155 - 158

2. Safety profile of Tysabri: international risk management plan

   • P. Iaffaldano
   • M. D’Onghia
   • Maria Trojano

   MS Treatment 01 November 2009 Pages: 159 - 162

3. The pharmacovigilance program on natalizumab in Italy: 2 years of experience

   • G. Tedeschi
   • M. P. Amato
   • G. L. Mancardi

   MS Treatment 01 November 2009 Pages: 163 - 165

4. Mitoxantrone: benefits and risks in multiple sclerosis patients

   • V. Martinelli
   • M. Radaelli
   • G. Comi

   MS Treatment 01 November 2009 Pages: 167 - 170

5. Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks

   • Luciano Rinaldi
   • P. Perini
   • P. Gallo

   MS Treatment 01 November 2009 Pages: 171 - 173

6. Autologous haematopoietic stem-cell transplantation in multiple sclerosis: benefits and risks

   • E. Capello
   • L. Vuolo
   • Gianluigi Mancardi

   MS Treatment 01 November 2009 Pages: 175 - 177

7. New oral drugs for multiple sclerosis

   • Claudio Gasperini
   • S. Ruggieri

   MS Treatment 01 November 2009 Pages: 179 - 183